Drug Trial Radar · NCT04573023
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
86
Actual
Start
Feb 14, 2022
Primary completion
Oct 31, 2027
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- JCR Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Conditions
- Mucopolysaccharidosis II
Interventions
JR-141Drug
IV infusion, 2.0 mg/kg/week
IdursulfaseDrug
IV infusion
JR-141 or IdursulfaseDrug
The subjects who have achieved the pre-specified criteria\* are able to change the drug. \*If a subject in Idursulfase group shows decline in their neurocognitive outcome, idursulfase can be switched to JR-141. If a subject in JR-141 group shows decline in their peripheral outcome, JR-141 will be switched to idursulfase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in levels of cerebrospinal fluid heparan sulfate from baseline (Cohort A)Time frame: Baseline to Week 53
- Change in the raw scores of cognitive testing measured from baseline (BSID-III) (Cohort A)Time frame: Baseline to Week 105
Locations
26 sites in 12 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
UCSF Benioff Children's Hospital Oakland
Oakland, California
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Minnesota
Minneapolis, Minnesota
Columbia University Irving Medical Center
New York, New York
University of North Carolina at Chapel Hill Medical School Wing E
Chapel Hill, North Carolina
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Hospital Universitario Austral
Buenos Aires, Argentina
Hospital de Clínicas de Porto Alegre
Porto Alegre, Brazil
Instituto de Genética e Erros Inatos do Metabolismo
São Paulo, Brazil
Fundación Cardio Infantil - Instituto de Cardiología
Bogotá, Colombia
Hôpital Femme Mère Enfant
Lyon, France
Chu De Montpellier Hopital Gui De Chauliac
Montpellier, France
Hôpital Armand Trousseau
Paris, France
Universitätsklinikum Giessen
Giessen, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
SphinCS GmbH
Höchheim, Germany
Universitätsmedizin Mainz
Mainz, Germany
Clalit Health Services Ha'Emek Medical Center
Afula, Israel
Sheba Medical Center
Ramat Gan, Israel
Osp. Pediatrico Bambino Gesù, IRCCS
Rome, Italy
Uniwersytecki Szpital Dziecięcy
Krakow, Poland
Hospital Sant Joan de Déu
Barcelona, Spain
Gazi University Medicine Faculty Hospital
Ankara, Turkey (Türkiye)
Ege University Children Hospital
Izmir, Turkey (Türkiye)
Great Ormond Street Hospital for Children NHS Trust - Metabolic Medicine
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.